OR-LATTICE-SEMICONDUCTOR
25.8.2021 22:02:13 CEST | Business Wire | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today expanded its growing portfolio of automotive products with the announcement of versions of the Lattice Certus™-NX FPGA family optimized for infotainment, advanced driver assistance systems (ADAS), and safety-focused applications. Built on the Lattice Nexus™ platform, these new Certus-NX devices combine automotive-grade features with best-in-class I/O density, power efficiency, small size, reliability, instant-on performance, and support for fast PCI Express (PCIe) and Gigabit Ethernet interfaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005002/en/
“Demand for automotive semiconductors is increasing as the ongoing trends towards automotive system electrification, autonomy, and connectivity have manufacturers looking for ways to deliver the advanced features and user experiences drivers are looking for in their next vehicle,” said Jay Aggarwal, Director of Silicon Product Marketing, Lattice Semiconductor. “With class-leading performance and power efficiency, support for popular I/O standards in a small form factor, and high reliability, our Certus-NX general purpose FPGAs make a compelling silicon platform for the next-generation automotive applications car makers are eager to provide to their customers.”
“As more automotive systems go digital, modern cars have essentially become mobile datacenters. Automotive developers need access to secure and reliable silicon solutions with fast I/O performance to ensure mission-critical automotive systems can perform their functions instantaneously,” said K. Ganesh Rao, Practice Head – FPGA Solutions, Tata Elxsi. “Lattice Certus-NX FPGAs provide the reliability, performance, and feature set we need to make tomorrow’s automotive applications possible.”
The latest Certus-NX FPGAs are ideal for automotive applications like motor control, LED control in in-vehicle infotainment (IVI) systems, in-vehicle networking (IVN), and sensor data co-processing in ADAS applications. Key features of Certus-NX FPGAs include:
- Low power consumption – Up to 4X lower power use than similar FPGAs, with a programmable back bias that enables user-selectable high performance or low power operating modes, depending on the needs of the application.
- Small form factor – Up to 3X smaller with up to 2X the I/O density per mm2 in comparison to similar competing FPGAs.
- Instant-on performance – Ultra-fast device configuration from SPI memory up to 12X faster than similar competing FPGAs, with individual I/O able to configure in just 3 ms, and full-device startup in only 8-14 ms, depending on device capacity.
-
Robust I/O interfacing capability – Lattice’s extensive Certus-NX I/O IP library includes:
- 1.5 Gbps differential I/O with performance up to 70 percent higher than competing FPGAs.
- 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3.
- Automotive certification and high reliability – Certus-NX FPGAs are AEC-Q100 qualified and provide up to 100X better soft error rate (SER) performance than similar FPGAs.
- Authentication and encryption – To protect bitstreams against unauthorized access, Certus-NX FPGAs support AES-256 encryption with ECDSA; they are currently the smallest FPGAs on the market to support ECDSA.
- Ease of use/design – Lattice Radiant® and Lattice Propel™ software tools help simplify and accelerate automotive system design. Certus-NX FPGAs are also supported by the Lattice mVision™ and Lattice sensAI™ solution stacks so designers can leverage the stacks’ modular hardware platforms, reference designs, neural network IP cores, and custom design services to accelerate automotive vision system design.
Automotive-grade versions of Certus-NX FPGAs are now sampling with select customers. For more information about the Lattice technologies mentioned above, please visit:
- www.latticesemi.com/Certus-NX
- www.latticesemi.com/LatticeNexus
- www.latticesemi.com/LatticeRadiant
- www.latticesemi.com/Propel
- www.latticesemi.com/mVision
- www.latticesemi.com/sensAI
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo , or Youku .
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005002/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
